11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
2 October 2023
Three leading charities collaborate to fight childhood cancers
New Partnership we3can to fund research into three most common childhood cancers Today (2nd October 2023), three leading cancer charities have launched a new collaboration in order to improve the…
9 May 2018
Sharing this exciting news: a treatment advance for childhood leukaemia
A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades
11 March 2022
Inquiry highlights the impact of COVID-19 on blood cancer services
A new report has recently been published, following an inquiry by the All-Party Parliamentary Group (APPG) on Blood Cancer and the APPG on Stem Cell Transplantation and Advanced Cellular Therapies, on the impact of Covid-19 on blood cancer services in the UK.
30 November 2023
Leukaemia UK invests in next generation of blood cancer trial leaders
This week, aspiring chief investigators of future cutting-edge blood cancer clinical trials took to Birmingham for the DIDACT Foundation’s inaugural Clinical Trials Workshop – an event funded by Leukaemia UK….